MedTrace Logo

A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

NCT03897868 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2022-07-14

No results posted yet for this study

Summary

A multicenter, randomized, double-blind, parallel, phase 2 study to assess dose-response relationship of HCP1803 in patients with essential hypertension

Conditions

Interventions

DRUG

HCP1803

HCP1803

DRUG

Amlodipine

Amlodipine

DRUG

Losartan

Losartan

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Moo-Yong Rhee, M.D., Ph.D. · Donggguk University Ilsan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-21
Primary Completion
2020-02-26
Completion
2020-02-26

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03897868 on ClinicalTrials.gov